Abstract
The concentrative nucleoside transporter CNT1 and equilibrated nucleoside transporter ENT1 mediate the cellular uptake of naturally occurring pyrimidine and purine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs, thereby regulating drug responses or toxicity at the target site. The objectives of this study were to analyze interindividual variations in the cellular accumulation of gemcitabine and to examine the correlation between the uptake of gemcitabine and expression levels of CNT1 and ENT1 transporters. Gemcitabine was a substrate for both CNT1 and ENT1 with higher affinity to CNT1 than to ENT1. The difference in gemcitabine uptake was 4.8-fold in peripheral blood mononuclear cells (PBMCs) from 10 subjects. Among these, the CNT1- and ENT1-mediated uptake of gemcitabine was 14.3- and 16.5-folds, respectively. CNT1-mediated gemcitabine uptake showed a higher correlation with the CNT1 expression level than did ENT1-mediated uptake with ENT1 expression level. In conclusion, CNT1 seemed to be a major contributing factor to gemcitabine uptake in PBMCs and showed 14.3-fold inter-individual variations. However, ENT1-mediated uptake of gemcitabine might compensate for the total uptake of gemcitabine; therefore, the variation in the apparent accumulation of gemcitabine was smaller than that of the individual transporters.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achiwa, H., Oguri, T., Sato, S., Maeda, H., Niimi, T., and Ueda, R., Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci., 95, 753–757 (2004).
Baldwin, S. A., Beal, P. R., Yao, S. Y., King, A. E., Cass, C. E., and Young, J. D., The equilibrative nucleoside transporter family, SLC29. Pflugers Arch., 447, 735–743 (2004).
Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., and Govindarajan, R., CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res., 71, 1825–1835 (2011).
Burke, T., Lee, S., Ferguson, P. J., and Hammond, J. R., Interaction of 2′,2′-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J. Pharmacol. Exp. Ther., 286, 1333–1340 (1998).
Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., and Cass, C. E., Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene, 22, 7524–7536 (2003).
Evans, W. E. and Relling, M. V., Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487–491 (1999).
Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., Iannopollo, M., Bevilacqua, G., Mosca, F., and Danesi, R., Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., 66, 3928–3935 (2006).
Gray, J. H., Mangravite, L. M., Owen, R. P., Urban, T. J., Chan, W., Carlson, E. J., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., and Giacomini, K. M., Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol., 65, 512–519 (2004).
Hammond, J. R., Lee, S., and Ferguson, P. J., [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. J. Pharmacol. Exp. Ther., 288, 1185–1191 (1999).
Kiss, A., Farah, K., Kim, J., Garriock, R. J., Drysdale, T. A., and Hammond, J. R., Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem. J., 352Pt 2, 363–372 (2000).
Kong, W., Engel, K., and Wang, J., Mammalian nucleoside transporters. Curr. Drug Metab., 5, 63–84 (2004).
Lane, J., Martin, T. A., Mcguigan, C., Mason, M. D., and Jiang, W. G., The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. J. Exp. Ther. Oncol., 8, 203–210 (2010).
Li, R. W., Tse, C. M., Man, R. Y., Vanhoutte, P. M., and Leung, G. P., Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur. J. Pharmacol., 568, 75–82 (2007).
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., Young, J. D., Belt, J. A., Crawford, C. R., and Cass, C. E., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 58, 4349–4357 (1998).
Mata, J. F., Garcia-Manteiga, J. M., Lostao, M. P., Fernandez-Veledo, S., Guillen-Gomez, E., Larrayoz, I. M., Lloberas, J., Casado, F. J., and Pastor-Anglada, M., Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol. Pharmacol., 59, 1542–1548 (2001).
Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., and Stieger, B., Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology, 44, 62–74 (2006).
Myers, S. N., Goyal, R. K., Roy, J. D., Fairfull, L. D., Wilson, J. W., and Ferrell, R. E., Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics, 16, 315–320 (2006).
Naito, T., Tokashiki, S., Mino, Y., Otsuka, A., Ozono, S., Kagawa, Y., and Kawakami, J., Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin. Pharmacol. Toxicol., 106, 310–316 (2010).
Smith, K. M., Ng, A. M., Yao, S. Y., Labedz, K. A., Knaus, E. E., Wiebe, L. I., Cass, C. E., Baldwin, S. A., Chen, X. Z., Karpinski, E., and Young, J. D., Electrophysiological characterization of a recombinant human Na+coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J. Physiol., 558, 807–823 (2004).
Ueno, H., Kiyosawa, K., and Kaniwa, N., Pharmacogenomics of gemcitabine: can genetic studies lead to tailormade therapy? Br. J. Cancer, 97, 145–151 (2007).
Ulrich, C. M., Robien, K., and Mcleod, H. L., Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer, 3, 912–920 (2003).
Valdes, R., Ortega, M. A., Casado, F. J., Felipe, A., Gil, A., Sanchez-Pozo, A., and Pastor-Anglada, M., Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology, 119, 1623–1630 (2000).
Weinshilboum, R., Inheritance and drug response. N. Engl. J. Med., 348, 529–537 (2003).
Wong, A., Soo, R. A., Yong, W. P., and Innocenti, F., Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev., 41, 77–88 (2009).
Zimmerman, E. I., Huang, M., Leisewitz, A. V., Wang, Y., Yang, J., and Graves, L. M., Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett., 583, 425–429 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, MK. Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells. Arch. Pharm. Res. 35, 921–927 (2012). https://doi.org/10.1007/s12272-012-0518-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0518-8